Skip to main content
Premium Trial:

Request an Annual Quote

Natera and BGI Genomics BGI/Natera Signatera Assay

Natera and BGI Genomics have launched the BGI/Natera Signatera Assay in China, making it available to biopharmaceutical customers and clinicians. 

Natera's Signatera assay, which has been utilized to identify molecular residual disease earlier than standard imaging in clinical studies of non-small cell lung, bladder, breast and colorectal cancers, is being offered in China in partnership with BGI under the Chinese brand name Hua Jian Wei. The assay can help facilitate innovative trial design and enable biopharmaceutical researchers to make better informed and more timely decisions. Pharmaceutical companies can access this assay in China through the BGI-Natera partnership.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.